In a new study, scientists at the University of Maryland and the Institut Pasteur show that bacteria evolve new abilities, such as antibiotic resistance, predominantly by acquiring genes from other bacteria. The researchers new insights into the evolution of bacteria partly contradict the widely accepted theory that new biological functions in bacteria and other [...]
The FDA’s marathon run toward a new set of regulations to govern the development of biosimilars is official. Regulators will host their first public meeting on follow-on drug regs, and you can expect to hear plenty from big companies like Amgen on the need for lengthy and expensive clinical trials.
Underscoring the rapid global shift of drug R&D into China, Eli Lilly announced plans to set up a new research center in Shanghai that will initially hire up about 100 scientists and support staff to explore new therapies for diabetes and its twin co-morbidities–obesity and cardiovascular disease.
Vaccination rates for children insured by commercial plans declined roughly four percentage points between 2008 and 2009. And experts fear that if this trend continues, the public’s health could be jeopardized. ”Rates had been gradually improving in the commercial plans. This was the first time we’d seen a drop–and it was a pretty big drop,” [...]
Venture capital investments declined sharply in the third quarter of 2010, according to the MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association based on data provided by Thomson Reuters. Venture capitalists invested $4.8 billion in 780 deals in the third quarter of 2010; these numbers reflect a decline in quarterly investment activity of [...]
Sanofi-Aventis is going to Harvard this fall for some post-grad work in drug development. The Big Pharma company–which has been trumpeting its intention to partner up with academics and biotech companies rather than rely entirely on its own in-house research–and the Ivy League institution announced a research pact this morning, with a special focus on [...]
Researchers at Karolinska Institutet have shown how stem cells, together with other cells, repair damaged tissue in the mouse spinal cord. The results are of potential significance to the development of therapies for spinal cord injury. There is hope that damage to the spinal cord and brain will one day be treatable using stem cells [...]
When the economic crisis reached its peak in 2009, biotech companies were hit hard. We buried 16 developers in our first annual Biotech Graveyard list last year, and while that number has dropped significantly in 2010, there were still eight biotechs that simply couldn’t find a buyer or the money necessary to continue their run. [...]
Biomedical researchers at the University at Buffalo have engineered adult stem cells that scientists can grow continuously in culture, a discovery that could speed development of cost-effective treatments for diseases including heart disease, diabetes, immune disorders and neurodegenerative diseases.
The news that Geron had finally received the FDA’s approval to start the world’s first human trial of an embryonic stem cell treatment marked a major milestone for the controversial field. But it also highlights just how far ESC treatments have lagged behind adult stem cell remedies in human studies.
You are currently browsing the weblog archives for 'Bioinformatics Market Potential' tag.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Biotech Trading Signals Pharma News Biotech News